224 related articles for article (PubMed ID: 32125178)
1.
Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
[No Abstract] [Full Text] [Related]
2. Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies.
Visentin R; Schiavon M; Giegerich C; Klabunde T; Man CD; Cobelli C
IEEE Trans Biomed Eng; 2019 Oct; 66(10):2889-2896. PubMed ID: 30735983
[TBL] [Abstract][Full Text] [Related]
3. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL
Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Pascucci C; Gambelunghe A; Bolli GB; Fanelli CG; Porcellati F
Diabetes Care; 2021 Jan; 44(1):125-132. PubMed ID: 33444161
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles.
Kawaguchi Y; Sawa J; Sakuma N; Kumeda Y
J Diabetes Investig; 2019 Mar; 10(2):343-351. PubMed ID: 29947060
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.
Martin ; Zhou Y; Takagi T; Tian YS
Int J Clin Pharm; 2022 Jun; 44(3):587-598. PubMed ID: 35476308
[TBL] [Abstract][Full Text] [Related]
8. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
[TBL] [Abstract][Full Text] [Related]
9. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
[TBL] [Abstract][Full Text] [Related]
10. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
[TBL] [Abstract][Full Text] [Related]
11. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
[TBL] [Abstract][Full Text] [Related]
12. In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects.
Sieber J; Weinheimer M; Kongable G; Riddle S; Chang YY; Flacke F
J Diabetes Sci Technol; 2020 Sep; 14(5):898-907. PubMed ID: 31288531
[TBL] [Abstract][Full Text] [Related]
13. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study.
Yamabe M; Kuroda M; Hirosawa Y; Kamino H; Ohno H; Yoneda M
J Diabetes Investig; 2019 Mar; 10(2):352-357. PubMed ID: 29989335
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins.
Buzzetti R; Fadini GP; Nicolucci A; Larosa M; Rossi MC; Cucinotta D;
Nutr Metab Cardiovasc Dis; 2022 Sep; 32(9):2255-2263. PubMed ID: 35961826
[TBL] [Abstract][Full Text] [Related]
16. A simulator with realistic and challenging scenarios for virtual T1D patients undergoing CSII and MDI therapy.
Estremera E; Cabrera A; Beneyto A; Vehi J
J Biomed Inform; 2022 Aug; 132():104141. PubMed ID: 35835439
[TBL] [Abstract][Full Text] [Related]
17. Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator
Visentin R; Schiavon M; Giegerich C; Klabunde T; Man CD; Cobelli C
Annu Int Conf IEEE Eng Med Biol Soc; 2018 Jul; 2018():4905-4908. PubMed ID: 30441443
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
Hompesch M; Patel DK; LaSalle JR; Bolli GB
Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
[TBL] [Abstract][Full Text] [Related]
19. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
20. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
Cheng AYY; Patel DK; Reid TS; Wyne K
Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
